Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Rocket Pharmaceuticals Price Target Raised to $30.00 at Cantor Fitzgerald (RCKT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Travere Therapeutics (TVTX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
-
Wen Acquisition Corp Announces the Pricing of $261,000,000 Initial Public Offering
-
Form 13F-NT Cantor Fitzgerald Europe For: Mar 31
-
Form 13F-NT CANTOR FITZGERALD & CO. For: Mar 31
-
Form 13F-HR CANTOR FITZGERALD, L. For: Mar 31
-
Form 10-Q Cantor Fitzgerald Income For: Mar 31
-
Exagen (XGN) PT Lowered to $7 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Neutral Rating on Expedia (EXPE)
-
Cantor Fitzgerald Reiterates Overweight Rating on Uber Inc. (UBER)
-
Cantor Fitzgerald Reiterates Overweight Rating on Acrivon Therapeutics Inc (ACRV)
-
Cantor Fitzgerald Reiterates Overweight Rating on Eledon Pharamceuticals (ELDN)
-
Cantor Fitzgerald Reiterates Overweight Rating on Belite Bio, Inc, ADR (BLTE)
-
Cantor Fitzgerald Reiterates Overweight Rating on Precigen Inc. (PGEN)
-
Cantor Fitzgerald Reiterates Overweight Rating on Rubrik Inc (RBRK)
-
Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD)
-
Cantor Fitzgerald Reiterates Overweight Rating on Vanda Pharmaceuticals (VNDA)
-
Cantor Fitzgerald Reiterates Overweight Rating on Astria Therapeutics (ATXS)
-
Cantor Fitzgerald Reiterates Overweight Rating on SoundThinking (SSTI)
-
Cantor Fitzgerald Reiterates Overweight Rating on UnitedHealth Group (UNH)
-
Intuitive Machines Inc. (LUNR) PT Raised to $16 at Cantor Fitzgerald
-
CyberArk Software (CYBR) PT Raised to $420 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Neutral Rating on Acadia Healthcare (ACHC)
-
Cantor Fitzgerald Reiterates Underweight Rating on Airbnb Inc. (ABNB)
-
Cantor Fitzgerald Downgrades Affimed Therapeutics (AFMD) to Neutral
-
Semler ScientificĀ® Reports First Quarter 2025 Financial Results, BTC Yield of 22.2% YTD; Now holds 3,808 BTC
-
AST SpaceMobile (ASTS) Enters $500M Equity Distribution Agreement
-
Cantor Fitzgerald Reiterates Overweight Rating on Annexon Biosciences (ANNX)
-
Cantor Fitzgerald Reiterates Overweight Rating on AST Spacemobile (ASTS)
-
Cantor Fitzgerald Reiterates Overweight Rating on Xenon Pharmaceuticals (XENE)
-
Cantor Fitzgerald Reiterates Overweight Rating on Arrowhead Pharma (ARWR)
-
Cantor Fitzgerald Reiterates Overweight Rating on Arcturus Therapeutics (ARCT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Archer Aviation Inc. (ACHR)
-
Cantor Fitzgerald Reiterates Neutral Rating on Polestar Automotive Holding Uk Plc (PSNY)
-
Cantor Fitzgerald Reiterates Overweight Rating on Agios Pharma (AGIO)
-
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
-
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results
-
Omeros (OMER) Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
-
Ā Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
-
Cantor Fitzgerald Reiterates Overweight Rating on Ouster Inc. (OUST)
-
Cantor Fitzgerald Reiterates Overweight Rating on Alkermes (ALKS)
-
PureCycle Technolgies (PCT) PT Lowered to $12 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Rocket Lab USA (RKLB)
-
Cantor Fitzgerald Reiterates Overweight Rating on Tesla (TSLA)
-
Cantor Fitzgerald Reiterates Neutral Rating on Lucid Group Inc. (LCID)
-
Cantor Fitzgerald Reiterates Neutral Rating on Rivian Automotive Inc (RIVN)
-
Cantor Fitzgerald Raises Price Target on Aurora Innovation Inc (AUR) to $12
-
Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
-
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates


